# biological assets
Latest news and articles about biological assets
Total: 2 articles found
China CRO ‘Hoards Monkeys, Sells Shares’: Major Holders Exit as Zhaoyan’s Earnings Mask Weak Core Business
Zhaoyan New Drug saw its shares tumble after major shareholders announced plans to sell their entire holdings, triggering a market rout. The company’s improved 2025 net profit projection is driven largely by non‑cash fair‑value gains on biological assets, while its core CRO business faces revenue decline and negative operating profit amid sector overcapacity and price competition.
China CRO Pumps Profits by Stockpiling Lab Monkeys and Cash — but Sustainability Is in Doubt
Zhaoyan New Drug posted a paradoxical 2025 outlook: lower revenue but sharply higher net profit driven mainly by fair‑value gains on biological assets — chiefly experimental monkeys — and returns from cash management. The company’s core laboratory services remain under pressure, and the profitability bump has prompted scrutiny about the sustainability of relying on asset revaluation and financial income rather than scientific capabilities.